ZYNE
NASDAQZynerba Pharmaceuticals Inc.
Zynerba Pharmaceuticals Inc. (ZYNE) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for ZYNE in the last 30 days. The most recent was published Feb 9, 2024.
Latest news
25 items- 13D/GSEC Form SC 13G/A filed by Zynerba Pharmaceuticals Inc. (Amendment)SC 13G/A - Zynerba Pharmaceuticals, Inc. (0001621443) (Subject)
- SECSEC Form 15-12G filed by Zynerba Pharmaceuticals Inc.15-12G - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
- SECSEC Form EFFECT filed by Zynerba Pharmaceuticals Inc.EFFECT - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
- INSIDERJones Kenneth T was granted 30,000 shares, closing all direct ownership in the company (SEC Form 4)4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
- INSIDERStephenson Pamela closing all direct ownership in the company (SEC Form 4)4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
- INSIDERFickenscher James E was granted 170,000 shares, closing all direct ownership in the company (SEC Form 4)4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
- INSIDERSebree Terri B was granted 170,000 shares, closing all direct ownership in the company (SEC Form 4)4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
- INSIDERFederici William J closing all direct ownership in the company (SEC Form 4)4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
- INSIDERRosenberger Brian was granted 120,000 shares, closing all direct ownership in the company (SEC Form 4)4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
- INSIDERCooper Warren D closing all direct ownership in the company (SEC Form 4)4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
- INSIDERParker Albert P was granted 85,000 shares, closing all direct ownership in the company (SEC Form 4)4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
- INSIDERButler John P. closing all direct ownership in the company (SEC Form 4)4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
- INSIDERMoch Kenneth I closing all direct ownership in the company (SEC Form 4)4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
- INSIDERAnido Armando was granted 240,000 shares, closing all direct ownership in the company (SEC Form 4)4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
- INSIDERKisner Daniel L closing all direct ownership in the company (SEC Form 4)4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
- SECSEC Form POS AM filed by Zynerba Pharmaceuticals Inc.POS AM - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
- SECSEC Form S-8 POS filed by Zynerba Pharmaceuticals Inc.S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
- SECSEC Form S-8 POS filed by Zynerba Pharmaceuticals Inc.S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
- NEWSNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder TherapiesHealthcare company Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) completed its previously announced acquisition of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) on Wednesday. What Happened Harmony's offer to acquire all outstanding shares of Zynerba for $60 million or $1.1059 per share in cash, plus one non-tradeable contingent value right (CVR) per share, representing the right to receive potential additional payments of up to $140 million or approximately $2.5444 in additional cash per share, subject to the achievement of specific clinical, regulatory and sales milestones expired at 5:00 p.m. ET time on Tuesday, October 10, 2023. Following the acceptance of the tendered shares, Harmony
- SECSEC Form S-8 POS filed by Zynerba Pharmaceuticals Inc.S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
- SECSEC Form S-8 POS filed by Zynerba Pharmaceuticals Inc.S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
- SECSEC Form S-8 POS filed by Zynerba Pharmaceuticals Inc.S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
- SECSEC Form S-8 POS filed by Zynerba Pharmaceuticals Inc.S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
- SECSEC Form S-8 POS filed by Zynerba Pharmaceuticals Inc.S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
- SECSEC Form S-8 POS filed by Zynerba Pharmaceuticals Inc.S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
ZYNE FAQ
7 questionsWhat does Zynerba Pharmaceuticals Inc. do?
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to...What is the latest news on ZYNE?
Quantisnow has not tracked any new filings, ratings or press releases for ZYNE in the last 30 days. The most recent wire item was published on February 9, 2024.Where does ZYNE stock trade?
Zynerba Pharmaceuticals Inc. (ZYNE) is listed on NASDAQ.What sector and industry is ZYNE in?
Zynerba Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zynerba Pharmaceuticals Inc. go public?
Zynerba Pharmaceuticals Inc. (ZYNE) completed its IPO in 2015.What companies are similar to ZYNE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ZYNE side-by-side with any of them on Quantisnow.How can I track ZYNE on Quantisnow?
Quantisnow aggregates Zynerba Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZYNE to receive live email and push alerts on every new disclosure.